Barry E. Greene
Net Worth
Last updated:
What is Barry E. Greene net worth?
The estimated net worth of Mr. Barry E. Greene is at least $624,669 as of 10 Nov 2022. He owns shares worth $407,909 as insider and has received compensation worth at least $216,760 in Sage Therapeutics, Inc..
What is the salary of Barry E. Greene?
Mr. Barry E. Greene salary is $54,190 per year as Pres, Chief Executive Officer & Director in Sage Therapeutics, Inc..
How old is Barry E. Greene?
Mr. Barry E. Greene is 62 years old, born in 1963.
What stocks does Barry E. Greene currently own?
As insider, Mr. Barry E. Greene owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) | Pres, Chief Executive Officer & Director | 46,940 | $8.69 | $407,909 |
What does Sage Therapeutics, Inc. do?
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Barry E. Greene insider trading
Sage Therapeutics key executives
Sage Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Albert J. Robichaud Ph.D. (64) Chief Scientific Officer
- Dr. Jeffrey M. Jonas (72) Chief Innovation Officer, Chair of the Science & Technology Forum and Director
- Mr. Barry E. Greene (62) Pres, Chief Executive Officer & Director
- Ms. Anne Marie Cook (63) Senior Vice President, Gen. Counsel & Sec.
- Ms. Kimi E. Iguchi (63) Chief Financial Officer & Treasurer